Search Hotels in Corte Madera

A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices.

Medicare Drug Price Negotiation - What Court's Decision Means for Americans

October 02, 2023

Via Benzinga

Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs

September 28, 2023

AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation

Via Benzinga

3 Dividend Stocks to Buy and Hold Until Retirement

September 28, 2023

Together, these stocks can also help diversify your portfolio by giving you exposure to different industries.

Via The Motley Fool

Bristol-Myers Squibb Unusual Options Activity For September 27

September 27, 2023

Via Benzinga

Looking Into Bristol-Myers Squibb's Recent Short Interest

September 18, 2023

Via Benzinga

2 Undervalued Dividend Stocks to Buy Now

September 13, 2023

These two pharma titans are proven income vehicles.

Via The Motley Fool

Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise

September 26, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023

September 26, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Via MarketBeat

3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street

September 25, 2023

None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.

Via The Motley Fool

Topics Artificial Intelligence

Exposures Artificial Intelligence

Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.

September 24, 2023

These three healthcare stocks to sell are waving red flags at investors who should pay attention or suffer the consequences.

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

September 23, 2023

Via Talk Markets

Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study

September 22, 2023

Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy...

Via Benzinga

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

September 22, 2023

Bristol Myers Squibb Announces Dividend

September 20, 2023

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison

September 18, 2023

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...

Via Benzinga

Exposures Product Safety

10 Health Care Stocks Whale Activity In Today's Session

September 15, 2023

Via Benzinga

The 3 Most Undervalued Pharma Stocks to Buy in September 2023

September 14, 2023

Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now.

Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth

September 14, 2023

Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein

Via Benzinga

Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day

September 14, 2023

Roz Brewer stepped down from leading Walgreens, and the next CEO is a tough choice. These three make the cut.

The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.

September 13, 2023

Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p

Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs

September 12, 2023

Via Benzinga

Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients

September 11, 2023

Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo...

Via Benzinga

How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug

September 11, 2023

This story was first published on the Benzinga India portal.

Via Benzinga

Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

September 11, 2023

Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study

September 09, 2023

There are pharma stocks to buy for each type of investor. This article explores the best options in the industry.

The 3 Best Pharma Stocks to Buy Now: September 2023

September 08, 2023

Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug

September 07, 2023

Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug...

Via Benzinga

Topics Intellectual Property Lawsuit

Exposures Financial Intellectual Property Legal

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

September 07, 2023